Skip to Content

Notice

Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Method of Inhibiting Side Effects of Pharmaceutical Compositions Containing Amphiphilic Vehicles or Drug Carrier Molecules

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

U.S. Army Medical Research and Materiel Command, DOD.

ACTION:

Notice.

SUMMARY:

In accordance with 37 CFR 404.6, announcement is made of the availability for licensing of U.S. Patent Application No. 09/183,375 entitled “Method of Inhibiting Side Effects of Pharmaceutical Compositions Containing Amphiphilic Vehicles or Drug Carrier Molecules” filed October 30, 1998. Foreign rights are also available (PCT/US98/23280). This patent has been assigned to the United States Government as represented by the Secretary of the Army.

ADDRESSES:

Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, Maryland 21702-5012.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664. Both at telefax (301) 619-5034.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

A method is provided for inhibiting or preventing toxicity and other unwanted effects (a) caused by solvents for pharmaceuticals which solvents or emulsifier contain amphiphilic molecules such as polyethoxylated oils or a derivative thereof, or (b) caused by a drug in a vehicle containing amphiphilic molecules such as phospholipids or derivative thereof, employing a complement inhibitor, and pharmaceutical compositions including a drug, solvent, or carrier containing amphiphilic molecules or derivatives thereof, and a complement inhibitor are also provided.

Start Signature

Luz D. Ortiz,

Army Federal Register Liaison Officer.

End Signature End Supplemental Information

[FR Doc. 01-26674 Filed 10-22-01; 8:45 am]

BILLING CODE 3710-08-M